Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives.
Alessandra Dall'AcquaMichele BartolettiNastaran Masoudi-KhoramRoberto SorioFabio PuglisiBarbara BellettiGustavo BaldassarrePublished in: Cancers (2021)
Alterations in components of the cell-cycle machinery are present in essentially all tumor types. In particular, molecular alterations resulting in dysregulation of the G1 to S phase transition have been observed in almost all human tumors, including ovarian cancer. These alterations have been identified as potential therapeutic targets in several cancer types, thereby stimulating the development of small molecule inhibitors of the cyclin dependent kinases. Among these, CDK4 and CDK6 inhibitors confirmed in clinical trials that CDKs might indeed represent valid therapeutic targets in, at least some, types of cancer. CDK4 and CDK6 inhibitors are now used in clinic for the treatment of patients with estrogen receptor positive metastatic breast cancer and their clinical use is being tested in many other cancer types, alone or in combination with other agents. Here, we review the role of CDK4 and CDK6 complexes in ovarian cancer and propose the possible use of their inhibitors in the treatment of ovarian cancer patients with different types and stages of disease.
Keyphrases
- cell cycle
- cell proliferation
- papillary thyroid
- small molecule
- estrogen receptor
- clinical trial
- squamous cell
- end stage renal disease
- metastatic breast cancer
- endothelial cells
- lymph node metastasis
- randomized controlled trial
- newly diagnosed
- chronic kidney disease
- cell death
- squamous cell carcinoma
- young adults
- combination therapy
- peritoneal dialysis
- prognostic factors
- replacement therapy
- phase iii